United States Rx was electroCore’s largest revenue line in fiscal 2025, bringing in $24.07M of $32.03M (75%).
| Contract with Customer, Sales Channel | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| United States Rx | — | — | $19.31M | $24.07M |
| Net Sales | — | $1.03M | — | — |
| Revenue From Contract With Customer Excluding Assessed Tax | $15.00K | — | — | — |
| General Wellness | — | — | $2.81M | $5.55M |
| Outside The United States | — | — | $1.79M | $1.89M |
| Tacs Tim | — | — | $1.20M | $422.00K |
| In License Or Other | — | — | $82.00K | $96.00K |
| Total | $15.00K | $1.03M | $25.18M | $32.03M |
electroCore brought in $32.03M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 27.2% from $25.18M in fiscal 2024. United States Rx was the largest at $24.07M (75.2%), ahead of General Wellness at $5.55M (17.3%) and Outside The United States at $1.89M (5.9%). The other two revenue lines brought in $518.00K combined.
Compared with fiscal 2024, General Wellness grew fastest, up 97.4% to $5.55M. Every revenue line above 2% of revenue grew.
electroCore began breaking out United States Rx in fiscal 2024, General Wellness in fiscal 2024, Outside The United States in fiscal 2024 and Tacs Tim in fiscal 2024. electroCore stopped reporting Net Sales ($1.03M in fiscal 2023) and Revenue From Contract With Customer Excluding Assessed Tax ($15.00K in fiscal 2022) as separate revenue lines.
United States was electroCore’s largest region in fiscal 2025, bringing in $30.08M of $32.03M (94%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | $23.33M | $30.08M | |||||
| Net Sales | — | $102.00K | — | — | |||||
| Revenue From Contract With Customer Excluding Assessed Tax | $139.00K | — | — | — | |||||
| United Kingdom | — | — | $1.67M | $1.70M | |||||
| Other Countries | — | — | $119.00K | $197.00K | |||||
| Germany | — | — | — | — | |||||
| Japan | — | — | $65.00K | $65.00K | |||||
| Other | — | — | — | — | |||||
| Total | $139.00K | $102.00K | $25.18M | $32.03M |
electroCore brought in $32.03M from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 27.2% from $25.18M in fiscal 2024. United States was the largest at $30.08M (93.9%), ahead of United Kingdom at $1.70M (5.3%) and Other Countries at $197.00K (0.6%). The remaining region, Japan, brought in $65.00K.
Compared with fiscal 2024, United States grew 28.9% to $30.08M and United Kingdom grew 1.7% to $1.70M.
electroCore began breaking out Other Countries in fiscal 2024 and Japan in fiscal 2024. electroCore stopped reporting Revenue From Contract With Customer Excluding Assessed Tax ($139.00K in fiscal 2022) and Net Sales ($102.00K in fiscal 2023) as separate regions.
Product was electroCore’s largest product and service line in fiscal 2025, bringing in $30.08M of $30.14M (100%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Product | $23.33M | $30.08M |
| License | $65.00K | $65.00K |
| Total | $23.40M | $30.14M |
electroCore brought in $30.14M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $32.03M it reports by contract with customer, sales channel, so these lines do not cover all of its revenue. Product was the largest at $30.08M (99.8%), ahead of License at $65.00K (0.2%).
electroCore (ECOR) reports its revenue by contract with customer, sales channel, by geography and by product and service. In fiscal 2025, United States Rx was its largest revenue line, bringing in $24.07M (75.2% of the total), followed by General Wellness at $5.55M (17.3%).
United States Rx was electroCore's largest revenue line in fiscal 2025, bringing in $24.07M, or 75.2% of the $32.03M total across its five revenue lines.
United States was electroCore's largest region in fiscal 2025, bringing in $30.08M, or 93.9% of the $32.03M total across its four regions.
Product was electroCore's largest product and service line in fiscal 2025, bringing in $30.08M, or 99.8% of the $30.14M total across its two product and service lines.
Among electroCore's revenue lines that make up at least 2% of revenue, General Wellness grew fastest in fiscal 2025, up 97.4% from $2.81M to $5.55M.
Every figure comes from electroCore's annual financial filings, as reported. Each line keeps the name electroCore gives it, and years follow its fiscal calendar.
electroCore's revenue by contract with customer, sales channel goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.